Gaining Control of Eosinophilic Disorders:

Program Description 

Eosinophilic granulomatosis with polyangiitis (EGPA) and hypereosinophilic syndrome (HES) are both rare types of eosinophilic disorders. Diagnosis and management of these disorders is challenging due to their complex and overlapping pathologic features and heterogeneous systemic involvement. Both disorders carry substantial risks of morbidity and mortality due to delayed diagnosis and inadequate treatment. Interleukin (IL)-5 is a key driver of pathophysiology; therapies targeting IL-5 or the IL-5 receptor are a mainstay of treatment. In this confidence-based clinical decision CALIBRATE symposium, Drs. Praveen Akuthota, Philip Seo, and Michael Wechsler will discuss EGPA and HES patient cases with real-world, point-of-care decision checkpoints paired with confidence ratings to improve diagnosis and treatment sequencing. 

Target Audience 

This program was designed to educate pulmonologists, rheumatologists, clinical immunologists/allergists, hematologists, and other specialists who identify and manage patients with hypereosinophilic syndrome (HES) or eosinophilic granulomatosis with polyangiitis (EGPA). 

Educational Objectives 

Upon completion of this activity, participants will be better prepared to:

• Discuss the burdens of EGPA and HES with a focus on the effects of delayed diagnosis and suboptimal treatment
• Diagnose EGPA or HES promptly based on symptomology, red flags, medical history, ancillary testing, and appropriate multidisciplinary collaboration
• Describe the mechanistic rationale and trial evidence for biologic therapies for patients with EGPA or HES 
• Construct biologic-based treatment regimens for EGPA or HES that optimize disease control, minimize corticosteroid use, and target long-term remission 

Physician Accreditation Statement 

Integritas Communications is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. 

Physician Credit Designation 

Integritas designates this enduring activity for a maximum of 1.5 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

Instructions to Receive Credit 

In order to receive credit for this activity, the participant must complete the posttest and program evaluation.  

Disclosures of Conflicts of Interest 

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias.  

All relevant financial relationships have been mitigated. 

The faculty have the following relevant financial relationships with ineligible companies: 

Praveen Akuthota, MD: Consulting Fees: Amgen, AstraZeneca, Connect Biopharma, Enveda, Gilead Sciences, Inc., GlaxoSmithKline, Regeneron, Sanofi, Vida Ventures; Contracted Research: 4D Molecular Therapeutics, Advanced Research Projects Agency for Health, AstraZeneca, Cystic Fibrosis Foundation, National Institutes of Health, ReCode, Sanofi  

Philip Seo, MD, MHS: Data Monitoring Committee: Amgen 

Michael E. Wechsler, MD, MMSc: Consulting AND/OR Advisory Honoraria: AbbVie, Aerogen, Apogee, Areteia Therapeutics, Arrowhead Pharmaceuticals, Avalo Therapeutics, Belenos Bio, Celldex, Connect Biopharma, Cytoreason, Eli Lilly, Enveda Therapeutics, Evommune, General Medicine, Gilead, Jasper Therapeutics, Kinaset, Kymera, Merck, MyBiometry, Niox, Pfizer, Phylaxis,  Pulmatrix, RAPT Therapeutics, Recludix Pharma, SpiroMedical, Tetherex Pharmaceuticals, Uniquity Bio, Zurabio; Consulting/Advising/Speaking Honoraria/Research: AstraZeneca, Amgen, Regeneron, GlaxoSmithKline, Sanofi/Genzyme Stock Options: Cellergy Pharma Inc.; Consulting Honoraria/Stock Options/Research: Upstream Bio 

The Integritas planners and managers have no relevant financial relationships to disclose. 

Disclosure of Unlabeled Use 

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications.  

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. 

Disclaimer 

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. 

Fee Information & Refund/Cancellation Policy 

There is no fee for this activity.

Contact Information 

For information about this program, please contact us at info@exchangecme.com.